89bio, Inc. Made Headway
Tue, Sep 13, 2022 at 07:19 PM
89bio, Inc. (ETNB:NASDAQ) jumped higher at $7, a gain of 40%. On Tue, Sep 13, 2022, ETNB:NASDAQ touched a New 2-Week High of $7. The stock appeared on our News Catalysts scanner on Wed, Sep 07, 2022 at 09:08 AM in the 'MISCELLANEOUS' category. From Tue, Aug 30, 2022, the stock recorded 77.78% Up Days and 60.00% Green Days
About 89bio, Inc. (ETNB:NASDAQ)
89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, BIO89-100, is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue.
Top 10 Gainers:
- Akero Therapeutics, Inc. (AKRO:NASDAQ), 136.76%
- Aditxt Inc. (ADTX:NASDAQ), 113.75%
- Comera Life Sciences Holdings Inc. (CMRA:NASDAQ), 101.04%
- NeuroBo Pharmaceuticals, Inc. (NRBO:NASDAQ), 79.32%
- 89bio, Inc. (ETNB:NASDAQ), 40%
- Motorsport Games Inc. (MSGM:NASDAQ), 28.14%
- Akouos Inc. (AKUS:NASDAQ), 28%
- Infobird Co. Ltd (IFBD:NASDAQ), 27.98%
- Golden Path Acquisition Corporation (GPCO:NASDAQ), 22.39%
- Ensysce Biosciences Inc. (ENSC:NASDAQ), 22.26%